ADPKP | Focused Autosomal Dominant Polycystic Kidney Disease Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history suggestive of autosomal dominant polycystic kidney disease.

AHUGP | Atypical Hemolytic Uremic Syndrome (aHUS)/Thrombotic Microangiopathy (TMA) /Complement 3 Glomerulopathy (C3G) Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history suggestive of atypical hemolytic uremic syndrome (aHUS), thrombotic microangiopathy (TMA), or complement 3 glomerulopathy (C3G).

ALAGP | Alagille Syndrome Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history suggestive of Alagille syndrome.

ALPGP | Alport Syndrome Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history suggestive of Alport syndrome. This test is also intended for establishing a diagnosis of Alport syndrome.

CASRG | CASR Full Gene Sequencing with Deletion/Duplication, Varies

This test is intended for providing a genetic evaluation of individuals with a personal or family history of familial hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, or autosomal dominant hypoparathyroidism (autosomal dominant hypocalcemia).

CFMP | Cystic Fibrosis, CFTR Gene, Variant Panel, Varies

This test is intended for confirming a clinical diagnosis of cystic fibrosis, reproductive risk refinement via carrier screening for individuals in the general population, and reproductive risk refinement via carrier screening for individuals with a family history when familial variants are not available.

CFSMN | Cystic Fibrosis and Spinal Muscular Atrophy Carrier Screen Panel, Varies

This test is intended for reproductive risk refinement via carrier screening for individuals in the general population for cystic fibrosis and spinal muscular atrophy.

CIDP | Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum

This test is intended for evaluating for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and related demyelinating peripheral neuropathies.

CIDPI | Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Interpretation, Serum

This test is intended for interpretation for CIDP/Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum.

CKDGP | Cystic Kidney Disease Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history of cystic kidney disease. This test is also useful for establishing a diagnosis of hereditary cystic kidney disease.

CMVC8 | Cytomegalovirus (CMV) CD8 T-Cell Immune Competence, Quantitative Assessment by Flow Cytometry, Blood

This test is intended for assessing cytomegalovirus (CMV)-specific immune competence in allo-hematopoietic stem cell transplantation patients who are at risk for developing late CMV disease (beyond day 100 after transplant).

CONCS | Contactin-1 IgG Cell Binding Assay, Serum

This test is intended for evaluating chronic inflammatory demyelinating polyradiculoneuropathy and related demyelinating peripheral neuropathies.

CSFP | Carrier Screen, Focused Panel, Varies

This test is intended for expanded carrier screening for reproductive risk assessment purposes.

EURO | Phospholipase A2 Receptor, Enzyme Linked Immunosorbent Assay, Serum

This test is intended for distinguishing primary from secondary membranous nephropathy.

FLARP | Free-Living Amebae, Molecular Detection, PCR, Varies

This test is intended for the diagnosis of primary amebic meningoencephalitis and granulomatous amebic encephalitis in spinal fluid and tissue in conjunction with clinical findings.

FMNPP | Motor Neuropathy Panel

GALMP | Galactosemia, GALT Gene, Variant Panel, Varies

This test is intended for confirming a diagnosis of galactosemia as indicated by enzymatic testing or newborn screening.

GLIC | CD8 T-Cell Immune Competence, Global, Blood

This test is intended for determining overimmunosuppression within the CD8 T-cell compartment, when used on transplant recipients and patients with autoimmune disorders receiving therapy with immunosuppressant agents.

GLICP | CD8 T-Cell Immune Competence Panel, Global, Whole Blood

This test is intended for determining over immunosuppression within the CD8 T-cell compartment, when used on transplant recipients and patients with autoimmune disorders receiving therapy with immunosuppressant agents

NEPHP | Comprehensive Nephrology Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history suggestive of hereditary kidney disease.

ORTHP | Orthostatic Proteinuria, Random, Urine

This test is intended for identifying a diagnosis or additional variants associated with the phenotype in patients who previously have had a negative or inconclusive whole exome sequencing test.

PAI1 | Plasminogen Activator Inhibitor Antigen, Plasma

This test is intended for identification of heredity elevation or deficiency of plasminogen activator inhibitor type 1.

PCAG | Protein C Antigen, Plasma

This test is intended for evaluating the significance of decreased functional protein C, especially when decreased protein C activity might be congenital rather than acquired (eg, due to oral anticoagulant effect, vitamin K deficiency, liver disease, or intravascular coagulation and fibrinolysis/disseminated intravascular coagulation).

PLA2I | Phospholipase A2 Receptor, Immunofluorescence, Serum

This test is intended for distinguishing primary from secondary membranous nephropathy in patients with low levels of anti-phospholipase A2 receptor (PLA2R) antibodies

PLA2M | Phospholipase A2 Receptor, Monitoring, Enzyme-Linked Immunosorbent Assay, Serum

This test is intended for distinguishing primary from secondary membranous nephropathy.

PMND1 | Primary Membranous Nephropathy Diagnostic Cascade, Serum

This test is intended for distinguishing primary from secondary membranous nephropathy using an algorithmic approach.

PRCON | Protein, Total, Random, Urine

This test is intended for diagnosing of orthostatic proteinuria.

RATO2 | Protein/Creatinine, Random, Urine

This test is intended for calculation of total protein concentration per creatinine concentration.

RBART | Bartter Syndrome Gene Panel, Varies

This test is intended for establishing a diagnosis of Bartter syndrome, and providing a genetic evaluation for patients with a personal or family history suggestive of Bartter syndrome.

RFSGS | Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history of steroid resistant nephrotic syndrome (SRNS).

RSCGP | Nephrocalcinosis, Nephrolithiasis, and Renal Electrolyte Imbalance Gene Panel, Varies

This test is intended for providing a genetic evaluation for patients with a personal or family history suggestive of a hereditary form of nephrocalcinosis, nephrolithiasis, or renal electrolyte imbalance.

THSD7 | Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum

This test is intended for distinguishing primary from secondary membranous nephropathy cases with antibodies against THSD7A.